Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Jumping Today

By George Budwell - Feb 16, 2018 at 1:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are bidding up the clinical-stage biotech's stock in anticipation of the release of data for its experimental flu vaccine.

What happened

As of 2:04 p.m. EST Friday, shares of the clinical-stage vaccine-maker Novavax (NVAX -0.27%) were up by about 14.5% on more than double the normal daily volume. What's all the fuss about?

Investors appear to be piling into this small-cap biotech's stock ahead of its forthcoming NanoFlu data release, expected some time this month. 

A bottle containing a vaccine and a syringe in the background.

Image Source: Getty Images.

So what

If the early-stage data is positive, Novavax will sport two blockbuster candidates in its clinical lineup -- the other being the company's much-maligned respiratory syncytial virus vaccine candidate, which is currently in a late-stage trial for pregnant women. 

Now what

While Novavax's stock is certainly behaving as if a news release is imminent, investors should bear in mind that this sudden price spike could just as easily be the work of day traders looking for a quick profit. Novavax, after all, doesn't have an exceptionally large institutional shareholder base, making it prone to wild intra-day price swings.

Having said that, the company's own timeline, offered up last December, gives it less than two weeks more to unveil NanoFlu's latest data points. Whether these early to mid-stage results will ultimately warrant the vaccine's further development, however, is another question altogether.

At the end of the day, I think it's hard to justify jumping into this stock ahead of this key clinical readout. Even if the data is positive, the company will need to issue a sizable secondary offering to fund its clinical activities, which will almost certainly result in a significant drop in share price. Novavax, at that point, would arguably be a far more attractive buy than it is today, as the company would be better capitalized and it would have two high-value clinical candidates in late-stage development. That's why I'm content to watch this speculative biotech from the safety of the sidelines for now. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$51.67 (-0.27%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.